International Clinical Trial: Open-label, randomized, phase II clinical study of camrelizumab combined with platinum-based doublet chemotherapy with or without low-dose intestinal irradiation as first-line treatment for advanced non-small cell lung cancer

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119639) titled 'Open-label, randomized, phase II clinical study of camrelizumab combined with platinum-based doublet chemotherapy with or without low-dose intestinal irradiation as first-line treatment for advanced non-small cell lung cancer' on March 2.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Cancer Hospital Affiliated of Shandong First Medical University

Condition: Immune-resistant advanced non-small cell lung cancer

Intervention: chemotherapy combined with immunotherapy group:chemotherapy combined with immunotherapy

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollm...